Generic Name and Formulations:
Gatifloxacin 0.3%; oph soln; contains benzalkonium chloride.
Indications for ZYMAR:
Susceptible infections of the conjunctiva.
Adults and Children:
<1yr: not established. ≥1yr: 1 drop every 2 hours while awake for 2 days (up to 8 times daily), then 1 drop 4 times daily while awake for 5 more days.
Remove contact lenses. Risk of corneal endothelial cell injury: do not administer into anterior chamber of the eye. Discontinue if superinfection or hypersensitivity occurs. Pregnancy. Nursing mothers.
Conjunctival irritation, increased lacrimation, keratitis, papillary conjunctivitis, chemosis, conjunctival hemorrhage, dry or red eye, eye discharge or pain, eyelid edema, headache, reduced visual acuity, taste disturbance.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC